Skip to main content
. Author manuscript; available in PMC: 2019 Nov 1.
Published in final edited form as: Mol Cancer Ther. 2018 Aug 14;17(11):2320–2328. doi: 10.1158/1535-7163.MCT-17-0897

Figure 6.

Figure 6.

Effect of in vivo CLR127 and radiation on DNA damage repair. Mice bearing human prostate carcinoma PC-3 xenografts were treated with CLR127 (30 mg/kg/dose x 1 dose), XRT (8 Gy x 1 fraction) or the combination of CLR127 and XRT. CLR127 was injected intravenously 72 hours prior to radiation administration to allow for maximal uptake. Tumors were harvested 24 hours after radiation. γH2AX expression in the tumor xenograft was examined by immunohistochemistry. Shown is the percentage of γH2AX positive cells obtained from average of twelve visual fields randomly selected from three tumors per each treatment condition: excipient control/no treatment; CLR127 only; radiation only (XRT); and radiation and CLR127 treatment. Bars represent standard error. Panels: examples of visual fields under microscopic examination (20x magnification). Upper: CLR127 (CLR) and XRT, lower: XRT only. ** p ≤ 0.001.